来自MSN19 天
A2 Biotherapeutics raises $80m to advance CAR-T therapies for solid tumours
US-based biotech company A2 Biotherapeutics (A2 Bio) has secured $80m in funding to advance its pipeline of chimeric antigen receptor (CAR)-T cell therapies for solid tumour cancers. The Series C ...
来自MSN11 个月
A2 Bio’s cell therapy gains FDA orphan drug status for colorectal cancer
A2 Biotherapeutics (A2 Bio ... The Tmod platform's dual-receptor design, comprising an activator that targets tumour cells and a blocker for normal cells, addresses the issue with other solid ...